UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 409

Sortiert nach

Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia

Biochemical pharmacology, 2011-07, Vol.82 (2), p.91-98

Schaub, Robert G.

2011

Link zum Volltext

Verfügbarkeit prüfen

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers

Circulation (New York, N.Y.), 2007-12, Vol.116 (23), p.2678-2686

2007

Link zum Volltext

Verfügbarkeit prüfen

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

Blood, 2011-05, Vol.117 (20), p.5514-5522

2011

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

Blood, 2011-01, Vol.117 (2), p.727-735

2011

Link zum Volltext

Verfügbarkeit prüfen

P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor

Arteriosclerosis, thrombosis, and vascular biology, 2015-04, Vol.35 (4), p.829

2015

Link zum Volltext

Verfügbarkeit prüfen

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals : The EPIC-Norfolk prospective population study

Journal of the American College of Cardiology, 2007-07, Vol.50 (2), p.159-165

2007

Link zum Volltext

Verfügbarkeit prüfen

Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control

International journal of molecular sciences, 2020-07, Vol.21 (14), p.5085

2020

Link zum Volltext

Verfügbarkeit prüfen

NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease

PloS one, 2017-02, Vol.12 (2), p.e0171067-e0171067

2017

Link zum Volltext

Verfügbarkeit prüfen

Aptamers as candidate therapeutics for cardiovascular indications

Current opinion in pharmacology, 2008-04, Vol.8 (2), p.147-152

2008

Link zum Volltext

Verfügbarkeit prüfen

A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletion

PloS one, 2013-09, Vol.8 (9), p.e76692-e76692

2013

Link zum Volltext

Verfügbarkeit prüfen

Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody

International journal of molecular sciences, 2020-06, Vol.21 (12), p.4317

2020

Link zum Volltext

Verfügbarkeit prüfen

ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion

Arteriosclerosis, thrombosis, and vascular biology, 2012-04, Vol.32 (4), p.902

2012

Link zum Volltext

Verfügbarkeit prüfen

A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1

Structure (London), 2009-11, Vol.17 (11), p.1476-1484

2009

Link zum Volltext

Verfügbarkeit prüfen

Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo

PloS one, 2015-10, Vol.10 (10), p.e0140729-e0140729

2015

Link zum Volltext

Verfügbarkeit prüfen

Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A

Nature medicine, 2003-08, Vol.9 (8), p.1020-1025

2003

Link zum Volltext

Verfügbarkeit prüfen

Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation

Thrombosis and haemostasis, 2008-02, Vol.99 (2), p.343

2008

Link zum Volltext

Verfügbarkeit prüfen

The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time

Thrombosis and haemostasis, 2007-08, Vol.98 (2), p.397

2007

Link zum Volltext

Verfügbarkeit prüfen

P-selectin and leukocyte microparticles are associated with venous thrombogenesis

Journal of vascular surgery, 2003-11, Vol.38 (5), p.1075-1089

2003

Link zum Volltext

Verfügbarkeit prüfen

The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma

Oncoimmunology, 2019-02, Vol.8 (2), p.e1546543-e1546543

2019

Link zum Volltext

Verfügbarkeit prüfen

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs

The Journal of pharmacology and experimental therapeutics, 2006-04, Vol.317 (1), p.236

2006

Link zum Volltext

Verfügbarkeit prüfen

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

Transfusion (Philadelphia, Pa.), 2010-05, Vol.50 (5), p.1079-1087

2010

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory potential of in vivo natural killer T (NKT) activation by NKTT320 in Mauritian-origin cynomolgus macaques

iScience, 2022-03, Vol.25 (3), p.103889-103889, Article 103889

2022

Link zum Volltext

Verfügbarkeit prüfen

The role of iNKT cells on the phenotypes of allergic airways in a mouse model

Pulmonary pharmacology & therapeutics, 2017-08, Vol.45, p.80-89

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis

Thrombosis and haemostasis, 2006-03, Vol.95 (3), p.469

2006

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury

Journal of medicinal chemistry, 2010-08, Vol.53 (16), p.6003-6017

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 409

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(374)
Mit Volltextzugriff
(368)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals : The EPIC-Norfolk prospective population study

Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control

NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease

Aptamers as candidate therapeutics for cardiovascular indications

A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletion

Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody

ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion

A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1

Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo

Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A

Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation

The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time

P-selectin and leukocyte microparticles are associated with venous thrombogenesis

The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

Immunomodulatory potential of in vivo natural killer T (NKT) activation by NKTT320 in Mauritian-origin cynomolgus macaques

The role of iNKT cells on the phenotypes of allergic airways in a mouse model

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury

Suchergebnisse filtern